Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026

Centessa Pharmaceuticals plc

Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.
Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.
Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.
Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.
Saha resignation not due to any disagreement with company's operations or policies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.